5.2
Impact Factor
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Corrigendum
Current Issue
Editorial
Erratum
Full Length Article
Full lenth article
Letter to Editor
Original Article
Research article
Retraction notice
Review
Review Article
SPECIAL ISSUE: ENVIRONMENTAL CHEMISTRY
5.3
Impact Factor
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Corrigendum
Current Issue
Editorial
Erratum
Full Length Article
Full lenth article
Letter to Editor
Original Article
Research article
Retraction notice
Review
Review Article
SPECIAL ISSUE: ENVIRONMENTAL CHEMISTRY
View/Download PDF

Translate this page into:

Original article
10 (
2
); 273-282
doi:
10.1016/j.arabjc.2014.03.009

Development and validation of simple RP-HPLC-PDA analytical protocol for zileuton assisted with Design of Experiments for robustness determination

Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dist: Dhule, MS 425 405, India
Institute of Chemical Technology, Matunga, Mumbai, MS 400 019, India

⁎Corresponding author. Address: Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Karwand Naka, Shirpur, Dist: Dhule, MS 425 405, India. Tel.: +91 9823691502; fax: +91 2563255189. atulshirkhedkar@rediffmail.com (Atul A. Shirkhedkar)

Disclaimer:
This article was originally published by Elsevier and was migrated to Scientific Scholar after the change of Publisher.
Tel.: +91 9860596387; fax: +91 2563255189.

Abstract

Graphical abstract

Abstract

A simple, rapid, sensitive, robust, stability-indicating RP-HPLC-PDA analytical protocol was developed and validated for the analysis of zileuton racemate in bulk and in tablet formulation. Development of method and resolution of degradation products from forced; hydrolytic (acidic, basic, neutral), oxidative, photolytic (acidic, basic, neutral, solid state) and thermal (dry heat) degradation was achieved on a LC – GC Qualisil BDS C18 column (250 mm × 4.6 mm × 5 μm) by isocratic mode at ambient temperature, employing a mobile phase methanol and (0.2%, v/v) orthophosphoric acid in ratio of (80:20, v/v) at a flow rate of 1.0 mL min−1 and detection at 260 nm. ‘Design of Experiments’ (DOE) employing ‘Central Composite Design’ (CCD) and ‘Response Surface Methodology’ (RSM) were applied as an advancement to traditional ‘One Variable at Time’ (OVAT) approach to evaluate the effects of variations in selected factors (methanol content, flow rate, concentration of orthophosphoric acid) as graphical interpretation for robustness and statistical interpretation was achieved with Multiple Linear Regression (MLR) and ANOVA. The method succeeded over the validation parameters: linearity, precision, accuracy, limit of detection and limit of quantitation, and robustness. The method was applied effectively for analysis of in-house zileuton tablets.

Keywords

Zileuton
Reversed-phase high-performance liquid-chromatography
Validation
Design of Experiments
1

1 Introduction

Zileuton [R,S (±) N-(1-(benzo [b]-thien-2-yl) ethyl)-N-hydroxyurea] (Fig. 1) is a racemic mixture having approximately equal therapeutic activities (Erdman, 1992) which selectively and reversibly inhibits 5-lypoxygenase potentiating leukotrienes (LT’s – LTA4, LTB4, LTC4, LTD4 and LTE4 (Rask-Madson et al., 1992); mostly indicated in inflammatory diseases akin to psoriasis, rheumatoid arthritis, asthma, multiple sclerosis, uveitis and inflammatory bowel syndrome. Zileuton is a very slightly soluble compound without any ionizable functional group (Qui et al., 1997). Recently, the molecule has been reported in the literature as a new efficient and safe anti-acne drug (Zouboulis, 2009) and employed in USA to treat asthma. The official monograph in the United States Pharmacopeia (United States Pharmacopeia 34-NF 29, 2011); mentioned assay of zileuton via RP-HPLC-UV with application of a mobile phase containing buffers, mentioned flow rate (1.5 mL min−1 and 2.2 mL min−1 for RS) and stationary phase (Spherisorb ODS1 chromatographic column, 10 μm). The objective of the present study is directed towards development of stability – indicating method which could offer some advantages with respect to speed of analysis, simplicity in determination along with simultaneous resolution of drug and impurities generated during stress studies (Snyder et al., 1997). Literature depicts very critical, rare and atypical reports for efficient analytical determination of zileuton viz… Preparative separation and analysis of the enantiomers of [14C] zileuton (Thomas and Surber, 1992), kinetics and mechanism of chemical degradation in aqueous solutions by HPLC (Alvarez and Slade, 1992), HPLC determination with its N-dehydroxylated metabolite in plasma (Granneman et al., 1995), simultaneous determination along with N-dehydroxylated metabolite in untreated rat urine using HPLC (Thomas and Albazi, 1996), electrochemical reduction behaviour of zileuton at a dropping mercury electrode by polarography (Shreedhar et al., 2010) and one report on solubility and stability characterization of zileuton in a ternary solvent system assisted with HPLC (Trivedi et al., 1996).

Chemical structure for zileuton.
Figure 1
Chemical structure for zileuton.

Recently, authors successfully developed, simple ‘Zero order UV-spectrophotometric’ and ‘First order derivative UV-spectrophotometric’, methods for determination of zileuton (Ganorkar et al., 2013a) and a novel high-performance thin-layer chromatography (HPTLC) and UV-spectroscopic area under curve (UV-AUC) methods for determination of zileuton racemate for efficient routine analysis of drug in bulk and pharmaceutical formulations (Ganorkar et al., 2013b).

Determination of robustness during analytical method validation is gaining immense significance with respect to; statistical quality control monitoring, study of the factors that negatively affects the quality in pharmaceutical analysis, processes such as transfer of analytical method protocol from donor site to acceptor site, strict regulations demanded by regulatory authorities and as per recent suggestions by FDA; the use of ‘Quality by Design’ (QBD) or ‘Design of Experiments’ (DOE) strategy is recommended to achieve these goals (Walter, 2011). ‘One Variable at a Time’ (OVAT) approach and ‘Design of Experiments’ (DOE) are two different possible ways; used to assess robustness (Dejaegher and Heyden, 2007) amongst these; DOE is usually employed to study the simultaneous variations of factors for a response (Murthy et al., 2013).

Literature revealed some design methodologies to assess robustness of method such as; full factorial design, fractional factorial designs, Asymmetrical Factorial Designs (AFD), Central Composite Design (CCD) either as Circumscribed or Face-centred (Dejaegher and Heyden, 2007), Doehlert Designs, Box–Behnken Design (BBD), Plackett–Burman Design (PBD), Star Designs (Goupy, 2005); assisted with graphical methods of interpretation such as Normal probability plot, half-normal probability plot, bar plot with or without limit value, counter plot, standardized pareto chart and response surface method (RSM) (Dejaegher and Heyden, 2007). If the method of analysis is fast and requires testing of few factors (three or less) a good choice for robustness testing may be CCD which is widely employed because of its high efficiency with respect to the number of runs required (Petkovska et al., 2008). RSM was applied to investigate behaviour of the response around optimized values of the factors (Ficarra et al., 2002) which allows studying complete interaction of effects produced due to all variables at a time and demonstrates the experimental region around centre of interest (Shrinubabu et al., 2007).

Hence, in continuation to our quest for developing simple, rapid, economical and effective methods for the analysis of zileuton racemate; authors of this manuscript hereby wish to put forth a reliable, sensitive stability-indicating RP-HPLC-PDA analysis of zileuton racemate; assisted with DOE and CCD for evaluation of robustness of developed method followed by graphical interpretation of data by RSM and statistical interpretation by ANOVA and MLR.

2

2 Experimental

2.1

2.1 Drugs and reagents

Zileuton standard was obtained as a gift sample from Biophore India Ltd. (Hyderabad, India), (85% w/v) orthophosphoric Acid (OPA), Hydrogen peroxide (30% w/v), Sodium starch glycolate (SSG) and Micro-crystalline Cellulose (MCC) were procured from Loba Chemie, India. Methanol (HPLC Grade), sodium hydroxide (NaOH) and hydrochloric Acid (HCl), were purchased from Merck Ltd., India. Double distilled water was used throughout the analysis.

2.2

2.2 Equipments and experimental conditions

Analysis was performed on UFLC – LC 20 AD (Shimadzu Corporation, Japan) consisting of LC – 20 AD binary solvent delivery system (pump), SPD-M20A diode array detector and CTO – 10 AS vp; column oven, a rheodyne injector with 20 μl loop and a Hamilton syringe (100 μl). Separations were achieved on a LC – GC Qualisil BDS C18 column (250 mm × 4.6 mm, 5 μm). Data collection and analysis were performed with LC-solution (Shimadzu Corporation, Japan). Stress degradation studies were assisted with i-Therm® AI-7981, thermostatic Water Bath with digital controller. All weighing operations for the present analysis were carried out with the help of SHIMADZU AUX-120 analytical balance. Ultrasonication of samples was performed using Ultrasonicator; ENERTECH Electronics Pvt. Ltd., India.

2.3

2.3 Preparation of in-house zileuton tablets

As the tablet formulation was not available in Indian market; tablets containing 600 mg of zileuton were prepared in-house using direct compression technique and employing SSG as super disintegrant and MCC as diluent. Prepared tablets were used as pharmaceutical formulation for further analysis.

2.4

2.4 Preparation of stock standard solution and study of calibration curve

Stock solution of zileuton was prepared with a concentration of 100 μg mL−1 in a mixture of methanol and (0.2% v/v) OPA (80:20 v/v). Determination of linearity involved analysis of six working solutions having concentrations 2 μg mL−1, 4 μg mL−1, 6 μg mL−1, 8 μg mL−1, 10 μg mL−1 and 12 μg mL−1, respectively; obtained by serial dilution of stock standard solution with mobile-phase. Resulted peak areas and concentrations were subjected to regression analysis to establish a relationship as calibration curve.

2.5

2.5 Preparation of sample solution

The sample solution was prepared from in-house formulated zileuton tablets. The quantity of pulverized tablet mass equivalent to 50 mg zileuton was transferred into 100 mL volumetric flask containing 25 mL of methanol, after ultrasonication for 20 min; volume was made up to the mark to get the concentration of 500 μg mL−1. The resulting solution was filtered through a 0.45 μm filter (Millifilter, Milford, MA, USA). From filtrate, appropriate volumes of solution were transferred using micropipettes into 10 mL volumetric flasks and the volume was made up to the mark with mobile phase to obtain the final concentrations of 8 μg mL−1. Resulting solutions were subjected to proposed method for further analysis.

2.6

2.6 Chromatographic conditions

HPLC system: UFLC– LC 20 AD (Shimadzu Corporation, Japan)
Detector: SPD– M 20 A (Diode array detector)
Column: LC– GC Qualisil BDS C18
Dimensions: (250 mm × 4.6 mm, 5 μm)
Mobile-phase: methanol: (0.2% v/v) OPA, (80:20 v/v)
Mode: Isocratic
Flow rate: 1.0 mL min−1
Temperature: Ambient temperature
Detection wavelength: 260 nm
Injection volume: 20 μL

2.7

2.7 Stress degradation studies for zileuton

The optimized LC method was used to study the degradation behaviour of the drug under various stress conditions. Stress studies were carried out as per ICH Q1A (R2) recommendations for hydrolysis, oxidation, thermal (dry heat stress) and Q1B recommendations for photolysis. The stressors, choice of its concentration and preparation of samples were based on pre-developed laboratory protocol. The optimized stressed conditions are enlisted in Table 1.

Table 1 Optimized stress conditions for zileuton and generated degradation products with corresponding retention time.
Stress conditions Stressor & its concentration Exposure condition Duration of exposure Degradants and respective retention time (tR) (min)
Hydrolysis
Acidic 0.5 N HCl 60 °C 12 h III (2.78), VII (5.15), IX (6.79)
Basic 0.1 N NaOH 60 °C 4 h II (2.54), III (2.78), IV (3.15), VII (5.15)
Neutral Distilled Water 80 °C 12 h II (2.54), III (2.78), IV (3.15), VII (5.15)
Oxidation 3% H2O2 RT 6 h I (2.42), IV (3.15), VI (4.87)
Photolysisb
Acidic 0.01 N HCl Sunlight 12 h for 2 days IV (3.15), VI (4.87), XII (7.42)
Basic 0.01 N NaOH Sunlight 12 h for 2 days V (3.6), VII (5.15), VIII (5.80), XI (7.31)
Neutral Distilled water Sunlight 12 h for 2 days VI (4.87), XIII (7.52)
Solid state Sunlight 12 h for 2 days I (2.42), III (2.78), VI (4.87)
Thermalc 100 °C 8 h I (2.42), III (2.78), VII (5.15), X (7.15)
Exposure of samples to direct sunlight during all conditions of photolysis.
Sample spread as thin layer exposed to dry heat in hot air oven.

As the drug was insoluble in water; hydrolytic stress was induced by dissolving 10 mg of drug in methanolic solution of stressor in a 10 mL volumetric flask and volume was made up to the mark. Resulting solution was transferred into a 50 mL round bottom flask (RBF); fitted with a reflux condenser and refluxed for specified period. Sample solution (0.1 mL) was withdrawn with a 1.0 mL pipette and neutralized. Volume of resulting solution was made up to 10 mL using mobile phase; in a 10 mL volumetric flask. Solution thus obtained was then subjected to chromatographic determination. Sample solutions from all stressed situations were diluted with mobile phase to achieve a final concentration of 10 μg mL−1 before injecting into HPLC system.

2.7.1

2.7.1 Acidic hydrolysis

Acidic hydrolytic stress was induced by dissolving an accurately weighed quantity of drug equal to 10 mg in 0.5 M methanolic HCl and resulting solution was refluxed at 60 °C for 12 h in a thermostatic water bath. Sample solution (0.1 mL) was withdrawn and subjected to neutralization using dilute methanolic NaOH solution and subjected to chromatographic analysis.

2.7.2

2.7.2 Basic hydrolysis

For alkaline hydrolysis; 10 mg of zileuton was weighed accurately as described before and dissolved in 0.1 M methanolic NaOH; refluxed at 60 °C for 4 h. Sample solution (0.1 mL) was withdrawn and neutralized with dilute methanolic HCl. Solution thus obtained was then subjected to chromatographic determination.

2.7.3

2.7.3 Neutral hydrolysis

To study the effect of hydrolysis in neutral environment 10 mg of drug was dissolved in a mixture of methanol and double distilled water (2:8 v/v) as described previously and refluxed at 80 °C for 12 h. Appropriate quantity of stress induced sample was withdrawn; diluted and resulting solution was subjected to analysis by the developed chromatographic method.

2.7.4

2.7.4 Oxidative degradation

Oxidative stress was induced to sample by dissolving 10 mg of drug in hydrogen peroxide (3% v/v) and volume was made up to the mark in a 10 mL volumetric flask. Resulting solution was kept in dark at room temperature for 6 h to avoid any degradation by combination of exposed light and oxidative stressor. An appropriate volume of stressed sample was withdrawn; diluted and introduced to optimized chromatographic conditions.

2.7.5

2.7.5 Photo degradation

Photolysis was carried out by exposing samples directly to sunlight in acidic (0.01 M HCl), basic (0.01 M NaOH) and neutral (distilled water) medium. Photolytic stress in solid state was induced by spreading sample as a thin layer; which was kept for 12 h for two days in all four cases. The samples were withdrawn; acidic and basic samples were neutralized; diluted and subjected to analysis by the developed chromatographic method.

2.7.6

2.7.6 Thermal (dry heat degradation)

Thermal stress study was conducted by placing approximate quantity of drug equal to 100 mg in a sealed ampoule and keeping it in a digital thermostatic block at 100 °C for 8 h. From stressed sample 10 mg of drug was weighed and dissolved in mobile phase and diluted up to the mark in 10 mL volumetric flask. Resulting solution was diluted as stated before and subjected to analysis.

3

3 Method validation

The optimized method was validated as to ensure it for linearity, precision, LOD, LOQ and robustness as per recommendations of International Conference on Harmonisation (ICH) guidelines (International Conference on Harmonisation, 2005).

3.1

3.1 Accuracy

Accuracy of the method was evaluated by spiking the drug standard in predetermined tablet solution at concentration levels of 80%, 100% and 120% and determined as percent recovery studies.

3.2

3.2 Precision

The precision for an analytical method illustrates information on the random errors. It represents the closeness of agreement between a series of measurements obtained from multiple sampling of the same homogenous sample under optimized conditions. It is divided into repeatability (intra-day precision), intermediate precision (inter-day precision).

Intra-day and inter-day precisions for present RP-HPLC-PDA analysis were determined by analysing, three different concentrations 4 μg mL−1, 6 μg mL−1 and 8 μg mL−1 using three repetitive measurements at each target concentration level.

3.3

3.3 Limit of detection (LOD) and limit of quantitation (LOQ)

The determination of LOD and LOQ was based on the average standard deviations of the responses and slopes of constructed calibration curves (n = 3) as described by ICH guidelines Q2 (R1). Hence sensitivity of the proposed method was estimated in terms of LOD and LOQ using formulae; LOD = 3.3 × ASD/S and LOQ = 10 × ASD/S; where, ‘ASD’ is the average standard deviation and ‘S’ is the slope of corresponding calibration curve. LOD and LOQ were estimated at lower range of calibration curve in between 2 μg mL−1 and 4 μg mL−1 at concentrations of 2 μg mL−1, 2.5 μg mL−1, 3.0 μg mL−1, 3.5 μg mL−1, and 4.0 μg mL−1.

3.4

3.4 Robustness and experimental design methodology for robustness

Method robustness was evaluated as per ICH to determine the constancy of the results when variables inherent to the method of analysis are varied deliberately and it depicts the reliability of the analytical procedure opted. Robustness testing was performed in order to obtain information about those critical parameters affecting the response (peak area, retention time and found concentration). To study the simultaneous variations of the factors on the considered responses, a multivariate approach DOE with CCD was applied. Simultaneous variations of the factors can be studied effectively using DOE approach which was applied efficiently to test method robustness. CCD was employed to obtain predictive model describing the changes in the responses within the experimental domain.

A CCD in ‘k’ factors require ‘2k’ factorial runs, ‘2k’ axial experiments, symmetrically spaced at ±α along each variable axis and at least one centre point. Two or five Central repetitions are generally carried out in order to know the experimental error variance and to test the predictive validity of the model (Lunsted et al., 1998). Statistical validation of polynomial equations generated by Design Expert® software (version 8.0.1, Stat-Ease Inc., Minneapolis, MN) was established by analysis of variance (ANOVA) and coefficients of second order quadratic model were estimated by least square regression. Multiple linear regression statistical models result in predictor equations incorporating interactive and polynomial terms for evaluation of mutual relationships between the input variations and output responses; quoted as second order polynomial with the form:

(1)
y = b 0 + b 1 x 1 + b 2 x 2 + b 3 x 3 + b 12 x 1 x 2 + b 13 x 1 x 3 + b 23 x 2 x 3 + b 11 x 1 2 + b 22 x 2 2 + b 33 x 3 2 where, ‘y’ is the measured response (dependent variable) associated with the each factor level combination; ‘b0’ represents the polynomial equation intercept representing average arithmetic mean of all quantitative outcomes of eighteen runs and ‘b1b33’ are regression coefficients computed from the observed experimental values of ‘y’. ‘x1’, ‘x2’ and ‘x3’ represent the coded levels of independent variables where x1: content of methanol (% v/v), x2: flow rate (mL min−1) and x3: concentration of OPA (% v/v); ranges selected for independent variables during determination of method robustness were; (75–85), (0.9–1.1) and (0.1–0.3), respectively for x1, x2, and x3. The optimized values obtained for x1, x2, and x3 were 80% v/v, 1.0 mL min−1 and 0.2% v/v, respectively. The x1x2, x1x3 and x2x3 represent the interaction terms. Polynomial terms x21, x22 and x23 are included to investigate the type of model. The considered responses were peak area (y1), retention time (min) (y2) and found concentration (%) (y3). The experimental domain of the selected variables is reported as represented in Table 2.
Table 2 Generated experimental domain for robustness testing and obtained responses.
Run Methanol (% v/v) (x1) Flow rate (mL min−1) (x2) Conc. of OPA (% v/v) (x3) Peak area (y1) Retention time (min) (y2) Found conc. (%) (y3)
1 75 0.9 0.1 455860 5.257 111.927
2 75 1.1 0.3 385007 3.64 94.44
3 85 1.1 0.3 369031 3.534 90.5
4 80 1 0.2 408121 4.199 100.146
5 85 1 0.2 411533 3.887 100.988
6 75 1.1 0.1 375242 4.33 92.0327
7 75 1 0.2 409320 4.71 100.44
8 85 0.9 0.3 452976 4.32 111.2153
9 80 1 0.3 410924 4.228 100.838
10 80 1 0.1 410457 4.256 100.7228
11 80 1.1 0.2 371488 3.844 91.10633
12 85 1.1 0.1 377748 3.56 92.6511
13 80 1 0.2 407734 4.196 100.05
14 85 0.9 0.1 451555 4.317 110.8646
15 80 0.9 0.2 452676 4.667 111.1413
16 80 1 0.2 408362 4.197 100.2058
17 80 1 0.2 408281 4.199 100.1858
18 75 0.9 0.3 449800 5.218 110.4316

Three dimensional surface responses were plotted to easily and more precisely define the effect of variations on method robustness which allowed predicting the behaviour of analyte slightly outside the experimental domain.

3.5

3.5 System suitability study

According to the United States Pharmacopeia, system suitability tests are integral part of liquid chromatographic methods. Retention time, capacity factor, number of theoretical plates, and asymmetry factor were calculated for standard solutions. The values for retention time (tR), capacity factor (k′), theoretical plates (N) and asymmetry factor obtained from system suitability study were found to be 4.201 min, 1.356, 5431.475 and 0.334, respectively. The data was found to be within acceptable limit.

4

4 Results and discussion

4.1

4.1 Optimization of chromatographic conditions

Different mobile phases were tested with a view to achieve simple, rapid and economical separation between drug and degradation products. The optimal mobile phase composition was found to be methanol (0.2% v/v) and orthophosphoric acid (80:20 v/v) and the run time was 10 min. Before analysis, both the mobile phase and sample solutions were filtered through a 0.45 μm membrane filter and degassed for 15 min in ultrasonicator. Chromatographic studies were performed at ambient temperature. The optimized flow rate was 1.0 mL min−1 with an injection volume 20 μl followed by detection at wavelength of 260 nm.

4.2

4.2 Linearity study

Determination of linearity and establishment of calibration curve involved plotting graph between peak areas obtained versus concentrations. Linear relationship was obtained for the concentration range of 2–12 μg mL−1 with a slope ± SD of 50,654 ± 183.22, intercept ± SD of 2296 ± 45.88 and correlation coefficient ± SD of 0.999 ± 0.0001. The regression equation obtained during determination of linearity was, y = 50,654 x + 2296.

4.3

4.3 Method validation

4.3.1

4.3.1 Accuracy

Accuracy of the developed method was evaluated in terms of percent recovery studies at three different levels 80%, 100% and 120%; percentage of drug recovered, when known amount of standard drug was added to pre-analysed samples and subjected to proposed HPLC method was 99.84% (% RSD 0.34), 101.21% (% RSD 0.88) and 99.79% (% RSD 0.87), respectively with mean percent recovery of 100.28%. The determination involved measurement in triplicate at each level with relative standard deviation in range of 0.34% to 0.87% with a mean percentage RSD of 0.70.

4.3.2

4.3.2 Precision

Intra-day and inter-day precisions were perceived using six repetitive measurements in target concentration level. The precision of developed method was evaluated in terms of % RSD. For intra-day and inter-day precision % RSD values were found to be in range of 0.23–0.27 and 0.42–0.46, respectively. Results for the intra-day and inter-day precision studies are represented in Table 3.

Table 3 Results from precision studies for RP-HPLC-PDA analysis of zileuton.
Drug Zileuton
Concentration (μg mL−1) Amount found in μg mL−1 [n = 9] ± SD RSD (%)
Intra-day precision
4 4.002 ± 0.009 0.23
6 6.005 ± 0.012 0.21
8 7.977 ± 0.022 0.27
Inter-day precision
4 3.997 ± 0.017 0.42
6 6.000 ± 0.014 0.23
8 7.955 ± 0.036 0.46

4.3.3

4.3.3 Limit of detection (LOD) and limit of quantification (LOQ)

The determination of LOD and LOQ was based on the standard deviations of the responses and slopes of constructed calibration curves (n = 3) as described by ICH guidelines Q2 (R1). The LOD and LOQ values found were 0.22 μg and 0.78 μg, respectively.

4.3.4

4.3.4 Robustness and design analysis for robustness

Three factor face centred design (FCD) consisting of eighteen experiments including four replicates at each centre point was used. All experiments were performed in randomized order to minimize the effects of uncontrolled factors that may introduce biased responses. Rather than analysis of single coefficient whole model equation was used and for response surface analysis; crucial focus was given to factors whose responses are with or without significance and are considered too. Equations obtained from the model were with the forms:

(2)
y 1 = 1216972 - 5743.39 x 1 - 768191 x 2 + 78179.93 x 3 - 3085.25 x 1 x 2 - 2750.25 x 1 x 3 + 71087.5 x 2 x 3 + 57.06 x 1 2 + 308221.40 x 2 2 + 169071.40 x 3 2
(3)
y 2 = 49.39 - 0.67804 x 1 - 24.1705 x 2 - 6.2119 x 3 + 0.2405 x 1 x 2 + 0.1765 x 1 x 3 - 8.5 x 2 x 3 + 0.002072 x 1 2 + 0.879762 x 2 2 - 0.47024 x 3 2
(4)
y 3 = 299.6321 - 1.41265 x 1 - 189.705 x 2 + 19.25577 x 3 - 0.76072 x 1 x 2 - 0.67807 x 1 x 3 + 17.51125 x 2 x 3 + 0.01405 x 1 2 + 76.10569 x 2 2 + 41.76419 x 3 2

Estimation of experimental error and measurement of validity of polynomial models (lack of fit) were obtained through repetition of experimental points (optimized level of variables). ANOVA was used to obtain regression lack of fit. As the calculated F-ratios were not greater than the tabled F-values at 95% confidence level there was no evidence of models lack of fit and the models were provided with adequate representation of data. Taking into account the degrees of freedom it was indicated that the data is well fitted to regression models as depicted in Table 4 (Ferreira et al., 2007).

Table 4 The estimates of CCD regression analysis and statistical parameters of ANOVA for robustness studies of zileuton.
Statistical parameters y1: Area y2: Retention time y3: Conc. of OPA
R2 a 0.9925 0.9782 0.9925
R2 adj. 0.9841 0.9537 0.9841
SDb 3752.5 0.1046 0.9258
C.V.%c 3752.5 2.4594 0.9157
DFd 9 9 9
SSe 14949836154.738 3.9335274801587 910.43549734121
MSf 1661092906.0821 0.43705860890653 101.15949970458
F-ratiog 117.964849 39.94223812197 118.02000249801
p-value <0.0001 <0.0001 <0.0001
Coefficient of regression.
Standard deviation.
Coefficient of variations.
Degrees of freedom.
Sum of squares.
Mean sum of squares.
Fischer’s ratio.

As per the values of coefficients from the polynomial models and their signs (Eqs. (2)–(4)), x1 (methanol content) and x2 (flow rate) have negative influence on the responses; y1 (peak area), y2 (retention time) and y3 (found concentration) while x3 (concentration of OPA) has the positive effect on y1 and y3 and negative effect on y2. Response surfaces from DOE revealed linear models (suggested) for all the three variables (x1, x2 and x3) and depicted least influences of the methanol content and concentration of OPA while flow rate showed the highest influence on area, retention time and found concentration; respectively. When concentration of OPA was kept constant; the increase in the content of methanol in mobile phase and flow rate leads to decrease in the peak area and retention time and increased found concentration of the analyte. Steepness of the response surface plots (Fig. 2A–I) demonstrates that when one of the factors was held constant at a specified level, usually the proposed optimum; deliberate change in the flow rate; affected peak area (y1) more as compared to other two factors (Fig. 2A and B). On the other side keeping flow rate constant (Fig. 2C, F, I) resulted in no considerable change in peak area and found concentration while retention time deviated slightly even though the methanol content and concentration of OPA varied notably; decrease in flow rate increased area and vice versa. Increase in the flow rate resulted in decreased found concentration and retention time (Fig. 2D, E, G, H), while the methanol content and OPA had no prevailing effect over the flow rate of mobile phase.

3D response surface plots for Area – peak area (y1), RT – retention time (y2) and FC – found concentration (y3); against flow rate vs. methanol content – (A), (D), (G); flow rate versus concentration of OPA (B), (E), (H) and concentration of OPA versus methanol content – (C), (F), (I).
Figure 2
3D response surface plots for Area – peak area (y1), RT – retention time (y2) and FC – found concentration (y3); against flow rate vs. methanol content – (A), (D), (G); flow rate versus concentration of OPA (B), (E), (H) and concentration of OPA versus methanol content – (C), (F), (I).

4.3.5

4.3.5 Assay of in-house zileuton tablet formulation

Assay of in-house zileuton tablets containing 600 mg of zileuton along with SSG and MCC was performed at a concentration of 8 μg mL−1. Percent drug content for zileuton in-house tablets was found to be 99.94% ± 0.54.

Summary of regression, validation and in-house tablet formulation assay parameters for stability indicating RP-HPLC-PDA analysis of zileuton is represented in Table 5.

Table 5 Summary of regression, validation and in-house tablet formulation assay parameters for stability indicating RP-HPLC-PDA analysis of zileuton.
Parameters RP-HPLC-PDA
Regression parameters results
Regression coefficient 0.999 ± 0.001
Slope ± SD 50,654 ± 183.22
Intercept ± SD 2296 ± 45.88
Concentration range [μg mL−1] 2–12
Validation parameters
Intra-day precision, n = 9 (RSD, %) 0.23–0.27
Inter-day precision, n = 9 (RSD, %) 0.42–0.46
Accuracy, n = 6 (mean recovery, % ± SD) 100.28% ± 0.70
LOD (μg) 0.22
LOQ (μg) 0.78
Robustness Robust
Tablet assay
Drug content (% ± SD) 99.94% ± 0.54

4.4

4.4 Stress degradation studies

Degradation products with their respective retention time (tR) and optimized stress conditions are represented in Table 1. Chromatogram for zileuton standard (Fig. 3A) depicted a single major peak at 4.0 min. Acidic hydrolysis resulted in three degradation products represented as III, VII and IX (Fig. 3B), four degradation products II, III, IV, and VII; were produced during basic hydrolysis (Fig. 3C), neutral hydrolysis showed four degradation products II, III, IV, and VII (Fig. 3D). Oxidative stress in 3% H2O2 (Fig. 3E), formed three degradation products I, IV, and VI while photolysis on exposure of drug in acidic medium produced degradants IV, VI and XII (Fig. 3F), in alkaline medium V, VII, VIII and XI (Fig. 3G), in neutral medium (Fig. 3H) only VI and XIII and in solid state stress (Fig. 3I) resulted in degradants I, III and VI. Exposure to dry heat (Fig. 3J) produced four degradants I, III, VII and X.

(A–J) Chromatograms, showing zileuton and its degradation products in various stress conditions applied (I–XIII are zileuton degradants in different stress conditions).
Figure 3
(A–J) Chromatograms, showing zileuton and its degradation products in various stress conditions applied (I–XIII are zileuton degradants in different stress conditions).

5

5 Conclusions

A simple and rapid stability-indicating RP-HPLC-PDA method was developed and validated successfully for the analysis of zileuton in bulk and in in-house tablet formulation. DOE and CCD were employed effectively for evaluation of robustness and statistical analysis showed that the model represents the phenomenon quite well and the variations in responses were correctly co-related to the variations of the factors. From results of ANOVA and analysis of response surfaces plots; it can be concluded that responses, y1, peak area; y2, retention time and y3, found concentration; are robust for x1 and x3 within selected range but for x2, flow rate; a precautionary statement should be included in the analytical procedure. The main advantages of the method over the USP method are the use of simplest mobile phase, optimum flow rate, low system pressure, and lower column length with simultaneous resolution of degradation products in isocratic mode. Stress studies revealed that drug was most susceptible to acidic and basic hydrolysis; susceptibility towards oxidative stress was lesser and least for photolytic and thermal (dry heat) stress and resulted in a total of thirteen degradation products (I– XIII).

Acknowledgments

Authors are thankful to Dr. S.J. Surana, Principal, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, (M.S.), India for providing necessary facilities to carry out the research work and Dr. Veena S. Belgamwar for her valuable suggestions during formulation of in-house tablets of zileuton.

References

  1. , , . Kinetics and mechanism of degradation of zileuton, a potent 5-lipoxygenase inhibitor. Pharm. Res.. 1992;9:1465-1473.
    [Google Scholar]
  2. , , . Ruggedness and robustness testing. J. Chromatogr. A. 2007;1158:138-157.
    [Google Scholar]
  3. , . Abbott Scientific Reports. Abbott Park, IL: Abbott Laboratories; .
  4. , , , , , , , , , , . Statistical designs and response surface techniques for the optimization of chromatographic systems. J. Chromatogr. A. 2007;1158:2-14.
    [Google Scholar]
  5. , , , , , , , , , . Validation of a LC method for the analysis of oxaliplatin in a pharmaceutical formulation using an experimental design. J. Pharm. Biomed. Anal.. 2002;29:1097-1103.
    [Google Scholar]
  6. , , , . Application of uv-spectrophotometry for determination of zileuton in bulk and in tablets. Indian Drugs. 2013;50:40-43.
    [Google Scholar]
  7. Ganorkar, S.B., Shirkhedkar, A.A., 2013. Novel HPTLC and UV-AUC analyses: for simple, economical, and rapid determination of zileuton racemate. Available from: <http://dx.doi.org/10.1016/j.arabjc.2013.05.013>.
  8. , . What kind of experimental design for finding and checking robustness of analytical methods? Anal. Chim. Acta. 2005;544:184-190.
    [Google Scholar]
  9. , , , . Determination of a new 5-lipoxygenase inhibitor, zileuton, and its inactive N-dehydroxylated metabolite in plasma by high performance liquid chromatography. Clin. Pharmacokinet.. 1995;29:1-8.
    [Google Scholar]
  10. , , , , , , , . Experimental design and optimization. Chemom. Intell. Lab. Syst.. 1998;42:3-40.
    [Google Scholar]
  11. International Conference of Harmonisation, 2005. Q2 (R1), validation of analytical procedures: text and methodology. In: International Conference on Harmonization, Geneva. Available from: <http://www.ich.org/LOB/media/MEDIA417.pdf>.
  12. , , , , , . Development and validation of RP-UPLC method for the determination of darifenacin hydrobromide, its related compounds and its degradation products using design of experiments. J. Pharm. Biomed. Anal.. 2013;72:40-50.
    [Google Scholar]
  13. , , , . Development and validation of rapid resolution RP-HPLC method for simultaneous determination of atorvastatin and related compounds by use of chemometrics. Anal. Lett.. 2008;41:992-1009.
    [Google Scholar]
  14. , , , , . Sustained-release hydrophilic matrix tablets of zileuton: formulation and in vitro/in vivo studies. J. Controlled Release. 1997;45:249-256.
    [Google Scholar]
  15. , , , , . Electrochemical reduction behaviour of zileuton at a dropping mercury electrode by polarography. E-J. Chem.. 2010;7:166-170.
    [Google Scholar]
  16. , , , , . 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. Agents and Actions. 1992;36(Suppl.):C37-C46.
    [CrossRef] [Google Scholar]
  17. , , , . Advanced HPLC Method Development (second ed.). Hoboken, NJ: John Wiley & Sons Inc.; .
  18. , , , , , . Development and validation of a HPLC method for the determination of voriconazole in pharmaceutical formulation using an experimental design. Talanta. 2007;71:1424-1429.
    [Google Scholar]
  19. , , . Preparative separation and analysis of the enantiomers of [14C] Zileuton, a 5-lipoxygenase inhibitor. J. Chromatogr. A. 1992;623:390-394.
    [Google Scholar]
  20. , , . Simultaneous determination of the 5-lipoxygenase Inhibitor “zileuton” and its N-dehydroxylated metabolite in untreated rat urine by micellar liquid chromatography. J. Liq. Chromatogr. Related Technol.. 1996;19:977-991.
    [Google Scholar]
  21. , , , . Solubility and stability characterization of zileuton in a ternary solvent system. Eur. J. Pharm. Sci.. 1996;4:109-116.
    [Google Scholar]
  22. United States Pharmacopeia 34-NF 29, through second supplement, Pharmacopeial Forum, Maryland, USA, 2011.
  23. , . Top 10 changes in FDA’s process validation guidance. BioProcess. Int.. 2011;9:72.
    [Google Scholar]
  24. , . Zileuton, a new efficient and safe systemic anti-acne drug. Dermato-Endocrinology. 2009;1:188-192.
    [Google Scholar]
Show Sections